Literature DB >> 6320367

Lymphokine production by cultured human T cells transformed by human T-cell leukemia-lymphoma virus-I.

S Z Salahuddin, P D Markham, S G Lindner, J Gootenberg, M Popovic, H Hemmi, P S Sarin, R C Gallo.   

Abstract

Cell-free conditioned media from human T cells transformed by human T-cell leukemia-lymphoma virus (HTLV-I) were tested for the production of soluble biologically active factors, including several known lymphokines. The cell lines used were established from patients with T-cell leukemia-lymphoma and from human umbilical cord blood and bone marrow leukocytes transformed by HTLV-I in vitro. All of the cell lines liberated constitutively one or more of the 12 biological activities assayed. These included macrophage migration inhibitory factor (MIF), leukocyte migration inhibitory factor (LIF), leukocyte migration enhancing factor (MEF), macrophage activating factor (MAF), differentiation inducing factor (DIF), colony stimulating factor (CSF), eosinophil growth and maturation activity (eos. GMA), fibroblast activating factor (FAF), gamma-interferon and, in rare instances, T-cell growth factor (TCGF). Some cell lines produced interleukin 3 (IL-3), platelet-derived growth factor (PDGF), or B-cell growth factors (BCGF). Such cells should prove useful for the production of lymphokines and as sources of specific messenger RNA's for their genetic cloning.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6320367     DOI: 10.1126/science.6320367

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  32 in total

1.  Effect of human T lymphotropic retrovirus-I exposure on cultured human glioma cell lines.

Authors:  B Macchi; B Caronti; M Pezzella; E Bonmassar; G Lauro
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

2.  Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40tax.

Authors:  I Lemasson; V Robert-Hebmann; S Hamaia; M Duc Dodon; L Gazzolo; C Devaux
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth.

Authors:  Y Wano; M Feinberg; J B Hosking; H Bogerd; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Isolation and sequencing of a cDNA clone homologous to the v-sis oncogene from human endothelial cells.

Authors:  B D Tong; S E Levine; M Jaye; G Ricca; W Drohan; T Maciag; T F Deuel
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

5.  Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies.

Authors:  C B Wilson; J Westall; L Johnston; D B Lewis; S K Dower; A R Alpert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Detection of human T cell lymphotropic virus type I proviral DNA and its gene expression in synovial cells in chronic inflammatory arthropathy.

Authors:  I Kitajima; K Yamamoto; K Sato; Y Nakajima; T Nakajima; I Maruyama; M Osame; K Nishioka
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  New entities in uveitis.

Authors:  S Lightman
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

Review 8.  Human T-lymphotropic retroviruses in adult T-cell leukemia-lymphoma and acquired immune deficiency syndrome.

Authors:  P S Sarin; R C Gallo
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

9.  The relationship between HTLV-I-infected cell lines and uveitis.

Authors:  A Fukushima; H Ueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-04       Impact factor: 3.117

10.  Human T lymphotropic virus type 1 uveitis after Graves' disease.

Authors:  K Yamaguchi; M Mochizuki; T Watanabe; K Yoshimura; M Shirao; S Araki; N Miyata; S Mori; T Kiyokawa; K Takatsuki
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.